Levetiracetam (Keppra)

Levetiracetam, widely known by its brand name Keppra, has emerged as one of the most important anticonvulsant medications in modern veterinary neurology for managing seizures in dogs. This medication represents a newer generation of anticonvulsants that offers several significant advantages over older drugs, including an excellent safety profile, minimal drug interactions, and effectiveness across a wide range of seizure types. Originally developed for human epilepsy treatment, levetiracetam has been enthusiastically adopted by veterinary neurologists and general practitioners alike for canine patients who require reliable seizure control. The drug's popularity has grown substantially in recent years as veterinarians have gained experience with its use and recognized its benefits for their patients.

The mechanism by which levetiracetam controls seizures is unique among anticonvulsant medications and not yet fully understood. The drug binds to a specific protein called synaptic vesicle protein 2A, or SV2A, which is involved in the release of neurotransmitters at synapses. By modulating this protein's function, levetiracetam appears to reduce the excessive neuronal firing that characterizes seizure activity without significantly affecting normal brain function. This distinctive mechanism means that levetiracetam works differently from other anticonvulsants like phenobarbital, which enhances GABA activity, or potassium bromide, which affects chloride conductance. The unique mechanism allows levetiracetam to be combined effectively with other anticonvulsants for dogs whose seizures are not adequately controlled with single-drug therapy.

Levetiracetam is available in multiple formulations that provide flexibility for different clinical situations and patient needs. Immediate-release tablets are the most commonly prescribed formulation for dogs, available in various strengths to accommodate patients of different sizes. Extended-release tablets offer the convenience of less frequent dosing, though their use in dogs requires careful consideration due to differences in canine gastrointestinal transit time compared to humans. An oral liquid solution allows precise dosing for very small dogs and facilitates administration to dogs who have difficulty swallowing pills. An injectable formulation is available for emergency situations or when oral administration is not possible, such as during active seizures or in hospitalized patients unable to take oral medications.

One of the most compelling features of levetiracetam is its favorable safety profile, which distinguishes it from many other anticonvulsant medications used in veterinary medicine. Unlike phenobarbital, levetiracetam does not undergo significant hepatic metabolism and therefore does not cause the liver enzyme induction or hepatotoxicity concerns associated with that older drug. This characteristic makes levetiracetam particularly valuable for dogs with liver disease or those already receiving other medications that affect the liver. The drug does not require routine blood monitoring for drug levels or organ function, reducing the burden and expense of long-term therapy for both owners and patients. While no medication is entirely without risks, levetiracetam's safety profile makes it an attractive first-line option for many dogs with epilepsy.

The primary indication for levetiracetam in veterinary medicine is the management of seizures in dogs with epilepsy, where it may be used as either a first-line treatment or as an adjunctive medication combined with other anticonvulsants. Idiopathic epilepsy, which refers to seizures with no identifiable underlying cause, is the most common seizure disorder in dogs and typically requires lifelong medication management. Levetiracetam has proven effective for controlling seizures in many dogs with idiopathic epilepsy, providing reliable suppression of seizure activity while maintaining good quality of life. The drug's favorable safety profile makes it an excellent choice for the long-term therapy that epileptic dogs require.

Refractory epilepsy, defined as seizures that persist despite appropriate therapy with one or more standard anticonvulsants, represents another important indication for levetiracetam use. Dogs whose seizures are not adequately controlled with phenobarbital, potassium bromide, or other first-line medications may benefit significantly from the addition of levetiracetam to their treatment regimen. The drug's unique mechanism of action allows it to provide additional seizure control through pathways not addressed by other medications, making it valuable in combination therapy. Many veterinary neurologists consider levetiracetam a preferred add-on medication when dogs require intensification of their anticonvulsant therapy because of its effectiveness and minimal interactions with other drugs.

Cluster seizures and status epilepticus, two of the most dangerous manifestations of canine epilepsy, represent acute situations where levetiracetam plays an important role. Cluster seizures, defined as multiple seizures occurring within a twenty-four-hour period, put dogs at risk for progression to status epilepticus and require aggressive intervention. The injectable formulation of levetiracetam allows rapid intravenous administration in emergency situations, and the drug is often included in hospital protocols for managing acute seizure events. Loading doses of levetiracetam can quickly achieve therapeutic blood levels, providing more rapid seizure control than would be possible with oral administration alone. Dogs with a history of cluster seizures may be sent home with oral levetiracetam to use as a pulse protocol during cluster events.

Beyond its use in classic epilepsy presentations, levetiracetam may be prescribed for dogs experiencing seizures secondary to other conditions, including brain tumors, inflammatory brain disease, or metabolic abnormalities. While treatment of the underlying condition is the primary goal in these cases, levetiracetam provides symptomatic seizure control during diagnosis and treatment. The drug's lack of significant hepatic metabolism makes it a safer choice for dogs whose seizures may be related to liver disease. Dogs recovering from brain surgery or other neurological procedures may receive levetiracetam prophylactically to reduce the risk of post-procedural seizures.

When selecting levetiracetam for a canine patient, veterinarians consider multiple factors including the severity and frequency of seizures, the dog's overall health status, concurrent medications, lifestyle factors, and owner capabilities. The drug may be chosen as a first-line anticonvulsant for dogs where the liver concerns associated with phenobarbital are particularly relevant, such as dogs with pre-existing hepatic disease or breeds predisposed to liver problems. Levetiracetam's lack of required blood monitoring makes it attractive for dogs whose owners have difficulty bringing them to the veterinary clinic for regular testing, or for dogs who are stressed by blood draws. The relatively high cost of levetiracetam compared to older generic anticonvulsants is a consideration, though generic versions have made the drug more affordable than when it was only available as brand-name Keppra.

Levetiracetam dosing in dogs requires individualized determination by a veterinarian based on the patient's weight, seizure characteristics, concurrent medications, and response to therapy. The drug demonstrates a wide therapeutic range, meaning there is a relatively large margin between effective doses and doses that cause toxicity, which provides flexibility in dosing but still requires professional guidance for optimal results. Accurate weight measurement is essential because levetiracetam doses are calculated based on body weight, and the significant size variation among dogs means that appropriate doses vary substantially between patients. Owners should not adjust doses without veterinary consultation, even if seizure control seems inadequate or side effects occur.

For routine maintenance therapy in dogs with epilepsy, levetiracetam is typically prescribed at doses ranging from 20 to 60 milligrams per kilogram of body weight daily, divided into two or three doses depending on the formulation used and individual patient factors. The immediate-release formulation is usually administered three times daily due to the relatively short half-life of levetiracetam in dogs, though some patients may achieve adequate control with twice-daily dosing. Dogs are often started at the lower end of the dosing range and the dose is adjusted based on seizure control and tolerability. Extended-release formulations may allow twice-daily dosing but require careful consideration because dogs metabolize levetiracetam faster than humans, and the extended-release mechanism may not provide consistently prolonged blood levels in all canine patients.

In emergency situations such as status epilepticus or cluster seizures, levetiracetam can be administered intravenously at loading doses of 30 to 60 milligrams per kilogram to rapidly achieve therapeutic blood levels. This loading dose may be followed by maintenance dosing to sustain seizure control. The intravenous formulation allows for precise dosing and rapid onset of action, making it valuable in hospital settings. For dogs with a history of cluster seizures, veterinarians may prescribe oral levetiracetam for pulse therapy, where owners give increased doses or additional doses at the first sign of cluster activity to help prevent seizure escalation. Specific protocols for pulse therapy vary and should be developed in consultation with the veterinarian based on the individual dog's seizure pattern.

Levetiracetam tablets can be given with or without food, though some dogs may experience less gastrointestinal upset when the medication is administered with a meal or treat. The tablets should be swallowed whole rather than crushed, particularly for extended-release formulations where crushing would destroy the slow-release mechanism. For dogs who have difficulty swallowing pills, the oral liquid solution provides an alternative that can be mixed with food or administered directly into the mouth. The liquid formulation allows precise dose adjustments for very small dogs where tablet sizes may not allow accurate dosing. Maintaining consistent timing between doses helps achieve stable blood levels and optimal seizure control.

If a dose of levetiracetam is missed, it should be given as soon as remembered unless it is nearly time for the next scheduled dose. If close to the next dose time, skip the missed dose and continue with the regular schedule. Never give double doses to compensate for a missed dose, as this increases the risk of side effects without necessarily improving seizure control. For dogs receiving levetiracetam three times daily, occasional single missed doses are unlikely to cause immediate breakthrough seizures in most patients, though consistent administration is important for optimal long-term control. Owners should document missed doses and discuss any pattern of missed doses with their veterinarian.

Unlike some other anticonvulsants, levetiracetam does not typically require gradual tapering when discontinuing therapy, though veterinarians may recommend a gradual dose reduction to monitor for recurrence of seizures. However, discontinuation of anticonvulsant therapy should only be done under veterinary supervision, as stopping medication can trigger recurrence of seizures in epileptic dogs. If levetiracetam is being used as add-on therapy and is to be discontinued while the dog continues other anticonvulsants, the veterinarian will provide specific guidance on the discontinuation process. Any changes to seizure frequency or severity during dose adjustments should be promptly reported to the veterinarian.

Levetiracetam is remarkably well-tolerated by most dogs, with side effects generally being mild, transient, and less common than with many other anticonvulsant medications. The favorable side effect profile is one of the primary reasons levetiracetam has become so popular in veterinary neurology, as dogs can often receive effective seizure control without the sedation, liver effects, or other concerns associated with older medications. Understanding potential side effects allows owners to monitor their dogs appropriately while maintaining realistic expectations about treatment. Most side effects that do occur tend to appear early in therapy and often resolve as the dog adjusts to the medication.

The most commonly observed side effects of levetiracetam in dogs include mild sedation, drowsiness, and decreased activity level, particularly during the initial period of therapy. These effects are generally less pronounced than those seen with phenobarbital and typically improve within the first few weeks of treatment as tolerance develops. Some dogs may experience ataxia, appearing slightly unsteady or wobbly, though this is usually mild and transient. Gastrointestinal effects including decreased appetite, nausea, vomiting, or changes in stool consistency occur in some dogs but are typically manageable and often improve with time or by administering the medication with food. Increased thirst and urination have been reported in some dogs receiving levetiracetam.

Behavioral changes represent a notable category of side effects that some dogs experience with levetiracetam. These changes can include restlessness, agitation, or irritability, and are sometimes described as the dog seeming anxious or unsettled. Paradoxically, while sedation is the most common behavioral effect, some dogs exhibit the opposite response and become more active or excitable. Changes in behavior are typically most noticeable when starting the medication or after dose increases and often diminish over time. If behavioral effects are pronounced or persistent, veterinarians may adjust the dose or consider alternative medications. Owners should document behavioral changes and discuss them with their veterinarian to determine whether adjustments are needed.

Moderate side effects warranting veterinary attention include persistent gastrointestinal upset that affects the dog's appetite or nutritional status, significant behavioral changes that impact quality of life or household harmony, or sedation that prevents normal activities. While levetiracetam does not require routine blood monitoring, any signs of unexplained illness during treatment should be evaluated. Excessive salivation has been reported in some dogs. Weight changes, either loss or gain, should be monitored and discussed with the veterinarian if significant. Dogs with pre-existing kidney disease should be monitored more closely, as levetiracetam is primarily eliminated through the kidneys.

Serious side effects with levetiracetam are rare, contributing to its reputation as a safe medication. Severe allergic reactions, though uncommon, can occur with any medication and would manifest as facial swelling, hives, difficulty breathing, or collapse. Any such symptoms require emergency veterinary care. There have been rare reports of blood cell abnormalities associated with levetiracetam use, though this is not a commonly recognized concern in dogs. Paradoxical worsening of seizure control is possible with any anticonvulsant and should prompt veterinary evaluation if suspected. Owners should report all observed side effects at follow-up appointments, as this information helps veterinarians optimize therapy. The overall excellent tolerability of levetiracetam means that most dogs can continue long-term treatment without significant adverse effects impacting their quality of life.

Levetiracetam should not be administered to dogs with known hypersensitivity or previous allergic reactions to the medication. While allergic reactions to levetiracetam are uncommon, any dog that has experienced symptoms such as facial swelling, hives, difficulty breathing, skin reactions, or other signs of allergic response following levetiracetam administration should not receive the drug again. Owners should inform their veterinarian of any previous adverse reactions to medications, as this history influences treatment decisions. Cross-reactivity with other medications is not a significant concern with levetiracetam due to its unique chemical structure, but complete medication history remains important for safe prescribing.

Significant kidney disease represents the primary organ-based consideration for levetiracetam use in dogs. Because levetiracetam is eliminated primarily through the kidneys without undergoing substantial hepatic metabolism, dogs with impaired renal function may experience accumulation of the drug and prolonged effects. This differs from many other anticonvulsants that are metabolized by the liver. Dogs with moderate to severe kidney disease may require dose reductions to prevent excessive drug accumulation and associated side effects. Veterinarians may prescribe lower doses or extend the interval between doses for patients with renal impairment. Regular monitoring of kidney function through blood work helps ensure safe ongoing therapy in dogs with known kidney concerns. Dogs with end-stage renal disease may require alternative anticonvulsants or very careful dose management.

Pregnancy and lactation considerations exist for levetiracetam, as with most anticonvulsant medications. The effects of levetiracetam on fetal development in dogs have not been thoroughly studied, and the drug should be used in pregnant dogs only when the benefits of seizure control clearly outweigh potential risks to developing puppies. Uncontrolled seizures during pregnancy also carry risks, creating a difficult balance that should be discussed with the veterinarian. Levetiracetam does pass into breast milk in humans, and the same is likely true in dogs, potentially affecting nursing puppies. If a nursing mother requires levetiracetam for seizure control, the veterinarian may recommend monitoring puppies for signs of sedation or arranging alternative nutrition. The decision to continue therapy during pregnancy and lactation requires careful consideration of individual circumstances.

Very young puppies may be more sensitive to levetiracetam's effects due to immature kidney function and developing nervous systems. While levetiracetam is sometimes necessary for puppies who experience seizures, careful dosing and close monitoring are essential in this population. The veterinarian will determine appropriate doses for young animals and may recommend more frequent follow-up to assess response and tolerability. Dogs with extremely poor overall health or multiple organ dysfunction may not be suitable candidates for any anticonvulsant therapy depending on their prognosis and goals of care. Complete disclosure of all health conditions, concurrent medications, and reproductive status allows the veterinarian to make the safest and most appropriate treatment recommendations for each individual patient.

One of the significant advantages of levetiracetam is its remarkably low potential for drug interactions compared to other anticonvulsant medications. Informing your veterinarian about all medications, supplements, and treatments your dog receives remains important, but the interaction profile of levetiracetam is much simpler than that of drugs like phenobarbital. This characteristic makes levetiracetam particularly valuable for dogs requiring multiple medications, as it can often be added to existing treatment regimens without complex dose adjustments or concerns about altered drug metabolism. The minimal interaction potential contributes to levetiracetam's popularity as both a first-line and add-on anticonvulsant in veterinary neurology.

The most clinically relevant interaction involving levetiracetam in dogs is the increased clearance that occurs when it is administered concurrently with phenobarbital. Phenobarbital induces hepatic enzymes that can increase the metabolism of many drugs, and while levetiracetam is not extensively metabolized by the liver, phenobarbital appears to increase its clearance through unknown mechanisms, possibly involving increased renal elimination. This interaction means that dogs receiving both medications may require higher doses of levetiracetam to achieve adequate seizure control compared to dogs receiving levetiracetam alone. Veterinarians account for this interaction when prescribing combination therapy and may need to adjust levetiracetam doses based on clinical response.

Levetiracetam does not significantly affect the metabolism or blood levels of other anticonvulsants, which simplifies combination therapy management. It can be safely combined with phenobarbital, potassium bromide, zonisamide, or other anticonvulsants without requiring dose adjustments of those medications based on interactions with levetiracetam. This characteristic is particularly valuable when adding levetiracetam to an established seizure management protocol, as the other medications can continue at their current doses while levetiracetam is titrated to effect. Similarly, levetiracetam does not interact significantly with common medications from other drug classes that epileptic dogs might receive, such as antibiotics, anti-inflammatories, or cardiac medications.

While formal drug interactions are minimal, additive effects should be considered when levetiracetam is combined with other medications that affect the central nervous system. The sedative effects of levetiracetam may be enhanced when combined with other sedating medications including phenobarbital, gabapentin, opioids, or antihistamines. This additive sedation is usually manageable and may even be beneficial in some cases, but owners should be aware of the potential for increased drowsiness when multiple sedating medications are used together. Any supplements with calming or sedative properties could similarly add to levetiracetam's effects. Owners should disclose all products their dog receives, including supplements perceived as natural or harmless, to ensure comprehensive awareness of potential additive effects. The minimal drug interaction profile of levetiracetam remains one of its most valuable characteristics for managing the complex needs of epileptic dogs.

Careful attention to dosing and administration instructions is essential for successful levetiracetam therapy in dogs. Veterinarians tailor doses to individual patients based on weight, seizure characteristics, and response to therapy, and owners should follow these instructions precisely. Dose adjustments should only be made in consultation with the veterinarian, even if seizure control seems inadequate or side effects are observed. Because levetiracetam doses are calculated based on body weight, accurate and current weight measurement is important, and significant weight changes should be communicated to the veterinarian so that doses can be recalculated if needed. The three-times-daily dosing schedule typical for immediate-release formulations requires commitment from owners to ensure consistent medication delivery.

Breed-specific considerations with levetiracetam are generally less pronounced than with some other medications used in veterinary medicine. The MDR1 gene mutation common in herding breeds does not significantly affect levetiracetam handling, as the drug's elimination does not depend on the transporters affected by this mutation. However, individual variation exists within any breed, and some dogs may be more sensitive to medication effects than others. Brachycephalic breeds do not have specific concerns with levetiracetam. Giant breeds may require larger total daily doses, potentially involving multiple tablets per dose, which can affect owner compliance and should be discussed during treatment planning. Toy breeds require precise dosing that may be easier to achieve with the liquid formulation.

Environmental and handling precautions for levetiracetam are straightforward but important for household safety. The medication should be stored securely away from children and other pets, as accidental ingestion could cause sedation and other effects. While levetiracetam tablets are not generally palatable to dogs, any medication should be kept out of reach of curious pets. Used medication containers should be properly disposed of, and expired or unused medication should be returned to a pharmacy or veterinary clinic for appropriate disposal rather than discarded in household trash. The non-controlled status of levetiracetam means that handling requirements are less stringent than for medications like phenobarbital, but responsible storage and disposal remain important.

Monitoring during levetiracetam therapy focuses primarily on seizure control and quality of life rather than laboratory parameters. Unlike phenobarbital, levetiracetam does not require routine blood monitoring for drug levels or liver function, though periodic general health assessments through physical examination and blood work remain appropriate for ongoing patient care. Owners should maintain a seizure diary documenting the date, time, duration, and characteristics of any seizure events, as well as notes about potential triggers or preceding changes. This information helps veterinarians assess whether therapy is effective and whether adjustments are needed. Any changes in seizure pattern, including increased frequency, severity, or new characteristics, should be reported promptly.

Special populations requiring additional consideration include dogs with kidney disease, who may need dose adjustments due to reduced drug clearance. Senior dogs may have age-related declines in kidney function that affect levetiracetam elimination even without diagnosed kidney disease. Puppies require careful dosing appropriate to their developmental stage. Dogs with chronic illnesses requiring multiple medications can generally receive levetiracetam safely due to its minimal interaction potential, but comprehensive medication review ensures no concerns are overlooked. Working dogs, service dogs, and performance dogs should be monitored for any effects that might impact their function, though levetiracetam's relatively mild side effect profile makes it a reasonable choice for these patients when seizure control is needed.

Proper storage of levetiracetam maintains the medication's effectiveness and ensures safety in homes with children and pets. Levetiracetam tablets and capsules should be stored at controlled room temperature, typically between 68 and 77 degrees Fahrenheit, in a dry location protected from moisture and light. Bathroom storage is not recommended due to humidity from showers and baths. The original container provides appropriate protection and contains important information about the medication. Heat sources and direct sunlight should be avoided, as excessive temperature can degrade medication potency over time. Checking expiration dates regularly ensures that medication will be effective when needed, and expired medication should be replaced rather than used.

Different formulations of levetiracetam have specific storage considerations that owners should understand. Immediate-release and extended-release tablets are generally stable at room temperature when stored appropriately. The oral liquid solution should be stored according to label directions, with some products requiring refrigeration after opening while others remain stable at room temperature. The liquid formulation should be kept in its original container with the cap tightly closed to prevent contamination. Injectable levetiracetam used in hospital settings has specific storage requirements that veterinary staff follow. Any changes in the appearance of tablets or color, odor, or consistency of liquid medication may indicate degradation, and such products should not be used.

Safety considerations around levetiracetam storage protect both children and pets in the household. While levetiracetam has a relatively favorable safety profile, accidental ingestion of multiple doses could cause significant sedation and other effects in children or unintended animal recipients. Child-resistant containers should be properly closed after each use. Other pets should be unable to access the medication, even though levetiracetam tablets are not typically appealing to animals. Multi-pet households should be particularly careful to prevent one pet from accessing another's medication during administration times. Unused or expired levetiracetam should be disposed of properly through pharmacy take-back programs, veterinary clinic disposal services, or community medication disposal events rather than discarded in household trash or flushed down toilets. Proper disposal prevents environmental contamination and eliminates the risk of accidental exposure.

Levetiracetam demonstrates consistent efficacy and safety across the diverse range of canine breeds, making it a versatile choice for seizure management regardless of breed-related factors. The drug's unique mechanism of action and renal elimination pathway mean that the breed-specific considerations that affect some other medications are generally not significant concerns with levetiracetam. Veterinarians can prescribe levetiracetam with confidence across breed categories, focusing primarily on individual patient factors such as seizure characteristics, concurrent health conditions, and lifestyle considerations. However, awareness of breed-related epilepsy patterns and general health tendencies helps optimize therapy for each patient.

The MDR1 gene mutation, which significantly affects the handling of many medications in herding breeds, does not substantially impact levetiracetam therapy. Dogs with this mutation, commonly found in Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, Border Collies, and related breeds, can typically receive standard levetiracetam doses without the concerns that accompany medications like ivermectin or loperamide. This makes levetiracetam a particularly attractive option for herding breed dogs who may need to avoid other medications due to MDR1 considerations. While genetic testing for MDR1 status remains valuable for overall medication planning, it does not typically influence levetiracetam dosing decisions. The safety of levetiracetam in MDR1-affected dogs is a meaningful advantage given the prevalence of epilepsy in some herding breeds.

Size considerations affect practical aspects of levetiracetam therapy across the breed spectrum. Giant breeds such as Great Danes, Irish Wolfhounds, Mastiffs, and Saint Bernards may require substantial daily doses that translate into multiple tablets per administration, which can affect owner compliance and medication costs. The availability of various tablet strengths helps optimize dosing for larger dogs. Conversely, toy breeds including Chihuahuas, Yorkshire Terriers, Pomeranians, and similar small dogs require precise dosing where small absolute errors represent larger proportional variations. The liquid formulation may be preferred for very small dogs to achieve accurate dosing. Mid-size breeds typically have straightforward dosing with standard tablet sizes. Regardless of breed size, accurate weight measurement is essential for calculating appropriate doses.

Certain breeds have recognized predispositions to epilepsy that may influence treatment planning. Breeds with higher epilepsy prevalence include Beagles, Belgian Tervurens, Bernese Mountain Dogs, Border Collies, German Shepherds, Golden Retrievers, Irish Setters, Keeshonden, Labrador Retrievers, Shetland Sheepdogs, Standard Poodles, and Vizslas, among others. For dogs of these breeds presenting with seizures, veterinarians may suspect idiopathic epilepsy earlier in the diagnostic process, though thorough evaluation remains important to rule out other causes. Understanding breed-specific seizure characteristics, such as the focal seizures common in some breeds, helps veterinarians select appropriate treatment and set realistic expectations for control. Age-related factors intersect with breed, as giant breeds reach geriatric status earlier than small breeds, potentially affecting kidney function and drug clearance. Regular veterinary assessment helps ensure therapy remains optimized as dogs age.

Several other anticonvulsant medications serve as alternatives or complements to levetiracetam in canine epilepsy management, each offering distinct characteristics that make them suitable for different clinical situations. Phenobarbital remains one of the most commonly prescribed anticonvulsants for dogs and is often used as a first-line treatment due to its proven efficacy, long track record, and low cost. However, phenobarbital requires regular blood monitoring for drug levels and liver function, and its hepatic enzyme induction can affect the metabolism of other medications. Potassium bromide offers an alternative that does not affect the liver and can be used alone or in combination with phenobarbital, though it requires an extended loading period to reach therapeutic levels and has its own monitoring requirements.

Zonisamide is another anticonvulsant frequently used in veterinary neurology, offering a different mechanism of action that makes it useful for combination therapy. Like levetiracetam, zonisamide has a relatively favorable safety profile compared to phenobarbital, though it does undergo hepatic metabolism. Gabapentin, while primarily used for pain management, also has anticonvulsant properties and may be part of combination protocols for refractory epilepsy. Diazepam and other benzodiazepines provide rapid-acting seizure control for emergency situations but are not suitable for long-term maintenance due to tolerance development. The choice among these medications depends on individual patient factors, including seizure type and frequency, concurrent health conditions, owner preferences, and practical considerations such as dosing frequency and monitoring requirements.

Complementary approaches may support seizure management alongside appropriate medication therapy. Dietary modifications, including medium-chain triglyceride supplementation and ketogenic-style diets, have shown promise for improving seizure control in some dogs, though they are not substitutes for anticonvulsant medication in dogs with significant seizure activity. Identifying and avoiding seizure triggers, maintaining consistent daily routines, ensuring adequate rest, and minimizing stress may help reduce seizure frequency in some patients. Regular exercise appropriate to the individual dog's condition contributes to overall health. Some owners explore integrative therapies such as acupuncture, though evidence for anticonvulsant effects is limited. All treatment decisions, including changes to medications or the addition of supplements, should be made in close consultation with a veterinarian experienced in epilepsy management. Owners should never adjust anticonvulsant doses or discontinue medications without veterinary guidance, as doing so can result in increased seizure activity or status epilepticus.